Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: Two-year follow-up of a new hybrid procedure compared with "on-pump" double bypass grafting
D. De Canniere et al., Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: Two-year follow-up of a new hybrid procedure compared with "on-pump" double bypass grafting, AM HEART J, 142(4), 2001, pp. 563-570
Citations number
39
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objective Percutaneous transluminal coronary angioplasty (PTCA) or surgery
can be chosen as first-line therapies in multiple-vessel coronary disease.
A mammary-to-left anterior descending (LAD) graft is the most important sta
tistical determinant of a favorable outcome after coronary artery bypass gr
afting (CABG) and can be performed with lower morbidity off pump through a
minithoracotomy. PTCA and stenting of the "non-LAD" vessels compete with CA
BG in terms of patency rates. Our purpose was to compare a combination of m
inimally invasive direct coronary artery bypass (MIDCAB) and PTCA with doub
le CABG as a treatment for double-vessel coronary artery disease involving
the proximal LAD.
Methods Two matched groups of 20 patients with double-vessel coronary disea
se undergoing either sequential MIDCAB and PTCA (group 1) or double CABG on
cardiopulmonary bypass (group 2) were compared. Angiographic control, comp
lications, hospital costs, quality of life, and 2-year follow-up of ischemi
a are reported.
Results All bypasses were patent at early control. Three adverse events wer
e noted in group 1 and 17 in group 2. The hybrid-procedure group exhibited
a shorter intensive care unit stay, fewer blood products transfused, less p
ain, better early quality of life, faster return to work, and similar cost.
Three patients required a second PTCA in group 1, one of which For resteno
sis. At 2 years all the patients are asymptomatic with no residual ischemia
.
Conclusions We conclude from this pilot study that the hybrid procedure is
feasible and appears to be a safe therapy for double-vessel coronary artery
disease and that it appears to generate less perioperative morbidity than
classic double CABG does. Therefore we believe that there is room to undert
ake prospective randomized studies on a larger-scale basis.